CD38 and plasma cell myeloma: Myeloma that is refractory to an immunomodulatory agent, a proteasome inhibitor, and monoclonal anti-CD38 antibody treatment (triple-class refractory) myeloma has emerged as a pressing need to find new effective management strategies.